SCHEMBL2805804

SCHEMBL2805804

COCCCOc1cc(CO)cc(OCc2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
LMNA P02545 2/20 0.52
NPC1 O15118 2/20 0.52
KDM4E B2RXH2 2/20 0.52
MAOB P27338 2/20 0.50
CYP4F2 P78329 1/20 0.48
CYP4A11 Q02928 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.46
TSHR P16473 1/20 0.46
RRM1 P23921 1/20 0.45
LTA4H P09960 1/20 0.44
EPHX2 P34913 1/20 0.44
CYP1A2 P05177 1/20 0.44
PTGS1 P23219 1/20 0.44
SLC6A2 P23975 1/20 0.44
CYP2C19 P33261 1/20 0.44
PTGS2 P35354 1/20 0.44
SLC6A3 Q01959 1/20 0.44
HIF1A Q16665 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2814524 0.93 MAOB (0.51) MEN1KMT2ALMNANPC1KDM4E
SCHEMBL13131323 0.87 MAOB (0.51) MEN1KMT2ALMNANPC1KDM4E
SCHEMBL4910012 0.86 MEN1 (0.62) MEN1KMT2ALMNAMAOBCYP4F2
SCHEMBL2809203 0.85 MAOB (0.50) MEN1KMT2ALMNANPC1KDM4E
SCHEMBL13433972 0.85 MAOB (0.53) MEN1KMT2ALMNANPC1KDM4E
SCHEMBL6035513 0.84 MAOB (0.65) MEN1KMT2ALMNAMAOBCYP4F2
SCHEMBL14601810 0.84 MEN1 (0.61) MEN1KMT2ALMNAKDM4EMAOB
SCHEMBL10922781 0.83 MAOB (0.54) MEN1KMT2ALMNANPC1KDM4E
SCHEMBL3488958 0.83 MEN1 (0.75) MEN1KMT2ALMNANPC1KDM4E
SCHEMBL28944701 0.83 MAOB (0.48) MEN1KMT2ALMNANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168952-B1 MORPHOLINE DERIVATIVES AS RENIN INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2017-02-15 EP disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
EP-2168952-A1 MORPHOLINE DERIVATIVE Mitsubishi Tanabe Pharma Corporation (JP) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240644-A1 MORPHOLINE DERIVATIVE REN, AGTR1, AGTR2 MEN1 167/4885KMT2A 1278/4885LMNA 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.